Elias Castanas

TL;DR: Data is presented supporting that the general opioid agonist Ethylketocyclazocine (EKC) decreases testosterone-BSA (a non-internalizable testosterone analog) induced PSA secretion, and reports that this opioid affects this non-genomic testosterone action, by modifying the distribution of the actin cytoskeleton in the cells, disrupting the signaling cascade.

TL;DR: Analysis of this interaction revealed that opioids modify the dimeric active form of NOS, through binding to the reductase part of the molecule, acting as non-competitive inhibitors of the enzyme, which opens interesting new possibilities for tumor biology and breast cancer therapy.

TL;DR: Oleylated B2 is a potent small-molecule agonist of mAR and could be a novel therapeutic agent for advanced prostate cancer, especially when taking into account the absence of androgenic actions and (liver) toxicity.

TL;DR: These data suggest that antisense BCMA may operate under physiological conditions using similar antisense-mediated control mechanisms, to inhibit the expression of the BCMA gene.

TL;DR: The effects of testosterone–BSA in two specifically modified pathways are explored, namely the non‐genotropic androgen signaling and the HIF1α pathway, revealing a new interaction of membrane‐acting androgen with EPOR and should be taken into account in the pharmaceutical manipulations of breast cancer patients.